Implications of Failure to Routinely Diagnose Resistance to Second-Line Drugs in Patients With Rifampicin-Resistant Tuberculosis on Xpert MTB/RIF: A Multisite Observational Study

BACKGROUND. Xpert MTB/RIF (Xpert) detects rifampicin-resistant tuberculosis (RR-tuberculosis), enabling physicians to rapidly initiate a World Health Organization–recommended 5-drug regimen while awaiting second-line drug-susceptibility test (DST) results. We quantified the second-line DST results t...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Clin Infect Dis
Autori principali: Jacobson, Karen R., Barnard, Marinus, Kleinman, Mary B., Streicher, Elizabeth M., Ragan, Elizabeth J., White, Laura F., Shapira, Ofer, Dolby, Tania, Simpson, John, Scott, Lesley, Stevens, Wendy, van Helden, Paul D., Van Rie, Annelies, Warren, Robin M.
Natura: Artigo
Lingua:Inglês
Pubblicazione: Oxford University Press 2017
Soggetti:
Major Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5434334/
https://ncbi.nlm.nih.gov/pubmed/28199520
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/cid/cix128
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi